Denosumab, an adjunctive method in central giant cell granuloma treatment: A case report

Akbar Rezaie; Zahra  Dalili Kajan; Donya Maleki; Reza  Shokuhi Fard; Hadi Golshekan

doi:10.18502/jcr.v8i4.11076

Akbar Rezaie Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht, Iran.
Zahra Dalili Kajan Department of Maxillofacial Radiology, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht, Iran.
Donya Maleki Student Research Committee, Faculty of Dentistry, Guilan University Of Medical Sciences, Rasht, Iran.
Reza Shokuhi Fard Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht, Iran.
Hadi Golshekan Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Guilan University of Medical Sciences, Rasht, Iran.

DOI: https://doi.org/10.18502/jcr.v8i4.11076

Keywords: Central giant-cell granuloma; Denosumab; Follow-up; Mandible.

Abstract

Central giant cell granuloma (CGCG) is a benign intraosseous pathology. A 17 years old male pa- tient was referred and diagnosed with CGCG from mandibular right first molar to mandibular left second premolar. Enucleation and curettage of the lesion were completed as the main treatment. Involved teeth on the right, 41, 42, 43, 44, and 45 (FDI) were extracted. As adjunctive therapy, 120 mg Denosumab was injected subcutaneously. The patient received sixteen sessions of therapy through 11 months. Two, sixteen, and eighteen months follow-up after the first session of injection showed an acceptable improvement in bone contour. The patient experienced no functional or aesthetic impairment. Alongside the promising results of Denosumab as adjunctive therapy in the management and treatment of diseases such as CGCG, some questions have remained unanswered and no protocol has been determined. The authors of the current study recommend further re- searches to confirm Denosumab as a potential adjunctive or alternative in the treatment of CGCG.